Stock Analiz

Puma Biotechnology, Inc. PBYI

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$7.77Market cap $402M
Open the interactive analysis →

Puma Biotechnology, Inc. (PBYI) is a healthcare company listed in the US with a market value of about $402M. In the twelve months to September 30, 2026 it had revenue of $232M and net income of $24M, a net margin of 10.3%.

Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).

Key numbers: a P/E of 16.9, a price to free cash flow of 8.7, 5-year revenue growth of 0% a year, a 5-year average ROIC of 14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 51% below the current price.

About Puma Biotechnology

Puma Biotechnology is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $28M in 2017 to $228M in 2025, growth of about 30.2% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 13% over three years (dilution for shareholders). It spends 27% of revenue on research and development.

Score: 2.6 / 5

Value3/5
Future growth2/5
Track record2/5
Financial health5/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year average ROIC above 12%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • Profitable 5 years in a row

Valuation

P/E (TTM)16.9
Forward P/E—
P/FCF8.7
P/S1.7
P/B2.7
EV/EBITDA8.9
PEG—
Dividend yield0.00%
FCF yield11.5%
Shareholder yield0.0%
Intrinsic value vs. price−51%

Growth and quality

Revenue growth (1 yr)-0.9%
Revenue growth (5 yrs, per year)0.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)4.9%
ROIC (5-yr avg.)13.6%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$232M$228M$230M$236M$228M$253M$225M$272M$251M$28M—
Net income$24M$31M$30M$22M$2000-$29M-$60M-$76M-$114M-$292M-$276M
Free cash flow$46M$42M$39M$27M-$16M$21M$727000$22M-$25M-$173M-$146M
EPS (diluted)$0.46$0.61$0.62$0.45$0.00$-0.72$-1.52$-1.95$-2.99$-7.85$-8.29
Net margin10.3%13.6%13.1%9.2%0.0%-11.5%-26.7%-27.8%-45.2%-1054.6%—
ROIC—20.4%14.6%18.6%13.4%0.9%-20.9%-22.4%-40.2%-226.9%-104.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Puma Biotechnology’s P/E ratio?

About 16.9, based on the last twelve months of diluted earnings per share.

Is Puma Biotechnology stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 51% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Puma Biotechnology pay a dividend?

Not currently.

Is Puma Biotechnology a good stock to buy?

We do not give buy or sell advice. Puma Biotechnology scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.